Publication Name	World Journal of Clinical Oncology
Manuscript ID	55638
Country	United Kingdom

Received	2020-03-29 23:42
Peer-Review Started	2020-03-29 23:53
To Make the First Decision
Return for Revision	2020-06-20 21:56
Revised	2020-07-29 20:19
Second Decision	2020-11-04 09:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-11-05 19:32
Articles in Press	2020-11-05 19:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-11-16 13:02
Publish the Manuscript Online	2020-11-18 14:20

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes
Manuscript Source	Invited Manuscript
All Author List	Laura Feeney, Ian JG Harley, W Glenn McCluggage, Paul B Mullan and James P Beirne
Funding Agency and Grant Number
Corresponding Author	James P Beirne, MBChB, PhD, Doctor, Trinity St James Cancer Institute, St. James’ Hospital, James’ Street, Dublin 8, Ireland. j.beirne@qub.ac.uk
Key Words	Epithelial ovarian cancer; Molecular profile; Liquid biopsy; Circulating tumor DNA; Biomarker discovery; Precision medicine
Core Tip	Epithelial ovarian cancer (EOC), particularly high-grade serous carcinoma, is a gynaecological malignancy with a poor survival rate. Currently there is no effective disease-specific biomarker, which could improve detection rates and treatment algorithms, for any of the EOC types - this is an area of unmet clinical need. Circulating tumour DNA (ctDNA) analysis has emerged as a potential blood-based “liquid biopsy” for early detection, diagnosis, staging and prognosis, monitoring response to treatment, monitoring minimal residual disease and relapse and identifying acquired drug resistance mechanisms. However, there are several obstacles to the development of cfDNA-based biomarkers which are discussed further in this in-depth review.
Publish Date	2020-11-18 14:20
Citation	Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World J Clin Oncol 2020; 11(11): 868-889
URL	https://www.wjgnet.com/2218-4333/full/v11/i11/868.htm
DOI	https://dx.doi.org/10.5306/wjco.v11.i11.868

Full Article (PDF)	WJCO-11-868.pdf
Full Article (Word)	WJCO-11-868.docx
Manuscript File	55638_Auto_Edited.docx
Answering Reviewers	55638-Answering reviewers.pdf
Audio Core Tip	55638-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	55638-Conflict-of-interest statement.pdf
Copyright License Agreement	55638-Copyright license agreement.pdf
Peer-review Report	55638-Peer-review(s).pdf
Scientific Misconduct Check	55638-Bing-Yu XQ-1.png
Scientific Misconduct Check	55638-Scientific misconduct check.pdf
Scientific Editor Work List	55638-Scientific editor work list.pdf